Effects of 5-campestenone (24-Methylcholest-5-en-3-one) on the type 2 diabetes mellitus model animal C57BL/KsJ-db/db mice

Hormone and Metabolic Research

Volumn 34, Issue 3, 2002, Pages 121-126

  Suzuki, Kunio ^a,b   Tanaka, M ^b   Konno, R ^b   Kaneko, Y ^b  

^a RIKEN   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

5 Campestenone; C57BL db db Mouse; Hypoglycemic Activity; Plasma Insulin; Type 2 Diabetes Mellitus Model Animal

Indexed keywords

5 CAMPESTENONE; CAMPESTEROL; FATTY ACID; GLUCOSE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALIA;

EID: 0036214107     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-23194     Document Type: Article

References (12)

1. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell-relationships
2. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
3. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
4. Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on mice
5. The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice
6. Selective oxidation of steroidal homoallylic alcohols using pyridium chlorochromate (PPC)
7. +-glucose cotransporter inhibitor T-1095
8. A pharmacologic profile of McN-3495 [N-(1-methyl-2-pyrrolidinylidene)-N′-phenyl-1- pyrrolidinecarboximidamide], a new, orally effective hypoglycemic agent
9. Selective potentiation of 5-methyl-2-(1-methylcyclohexyl)-4-oxazoleacetic acid (AD-4610) on glucose-induced secretion
10. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals
11. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats